基于粪便的大肠病变检测对普通风险人群的诊断效果：真实世界证据研究

IF 2.8 4区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Journal of clinical gastroenterology Pub Date : 2024-08-01 DOI:10.1097/MCG.0000000000002053

Catherine Cheney, Alice Parish, Donna Niedzwiecki, Chukwuemeka Oko, Christy Walters, Brian A Sullivan

{"title":"基于粪便的大肠病变检测对普通风险人群的诊断效果：真实世界证据研究","authors":"Catherine Cheney, Alice Parish, Donna Niedzwiecki, Chukwuemeka Oko, Christy Walters, Brian A Sullivan","doi":"10.1097/MCG.0000000000002053","DOIUrl":null,"url":null,"abstract":"Objective: We assessed the real-world performance of stool-based tests (SBTs) for colorectal cancer screening.Materials and methods: Retrospective review of average-risk individuals with positive SBT for advanced neoplasia (adenocarcinoma, advanced adenoma, and/or advanced serrated lesions) detection at follow-up colonoscopy.Results: There was no statistical difference in the detection of advanced neoplasia (P= 0.16) between SBTs [30.7% for multitargeted stool DNA (mt-sDNA) vs 22.8% for fecal immunochemical test]. However, there was a significant difference in the detection of advanced serrated lesions (11.3% for mt-sDNA vs 1.8% for fecal immunochemical test, P< 0.001).Conclusion: There was no difference between SBTs for advanced neoplasia detection, though mt-sDNA detected significantly more advanced serrated lesions.","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diagnostic Performance of Stool-based Testing for Colorectal Lesions Among Average-risk Individuals: A Real-world Evidence Study.\",\"authors\":\"Catherine Cheney, Alice Parish, Donna Niedzwiecki, Chukwuemeka Oko, Christy Walters, Brian A Sullivan\",\"doi\":\"10.1097/MCG.0000000000002053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: We assessed the real-world performance of stool-based tests (SBTs) for colorectal cancer screening.Materials and methods: Retrospective review of average-risk individuals with positive SBT for advanced neoplasia (adenocarcinoma, advanced adenoma, and/or advanced serrated lesions) detection at follow-up colonoscopy.Results: There was no statistical difference in the detection of advanced neoplasia (P= 0.16) between SBTs [30.7% for multitargeted stool DNA (mt-sDNA) vs 22.8% for fecal immunochemical test]. However, there was a significant difference in the detection of advanced serrated lesions (11.3% for mt-sDNA vs 1.8% for fecal immunochemical test, P< 0.001).Conclusion: There was no difference between SBTs for advanced neoplasia detection, though mt-sDNA detected significantly more advanced serrated lesions.\",\"PeriodicalId\":15457,\"journal\":{\"name\":\"Journal of clinical gastroenterology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MCG.0000000000002053\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCG.0000000000002053","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的我们评估了粪便检验（SBT）在结直肠癌筛查中的实际表现：对随访结肠镜检查时发现晚期肿瘤（腺癌、晚期腺瘤和/或晚期锯齿状病变）的 SBT 阳性的平均风险人群进行回顾性研究：不同 SBT 对晚期肿瘤的检出率无统计学差异（P= 0.16）[多靶向粪便 DNA（mt-sDNA）为 30.7%，粪便免疫化学检测为 22.8%]。然而，在晚期锯齿状病变的检出率方面却存在显著差异（mt-sDNA 检测为 11.3% vs 粪便免疫化学检测为 1.8%，P< 0.001）：结论：尽管 mt-sDNA 检测出的晚期锯齿状病变明显多于粪便免疫化学检测，但两种 SBT 检测晚期肿瘤的结果没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Diagnostic Performance of Stool-based Testing for Colorectal Lesions Among Average-risk Individuals: A Real-world Evidence Study.

Objective: We assessed the real-world performance of stool-based tests (SBTs) for colorectal cancer screening.

Materials and methods: Retrospective review of average-risk individuals with positive SBT for advanced neoplasia (adenocarcinoma, advanced adenoma, and/or advanced serrated lesions) detection at follow-up colonoscopy.

Results: There was no statistical difference in the detection of advanced neoplasia (P= 0.16) between SBTs [30.7% for multitargeted stool DNA (mt-sDNA) vs 22.8% for fecal immunochemical test]. However, there was a significant difference in the detection of advanced serrated lesions (11.3% for mt-sDNA vs 1.8% for fecal immunochemical test, P< 0.001).

Conclusion: There was no difference between SBTs for advanced neoplasia detection, though mt-sDNA detected significantly more advanced serrated lesions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of clinical gastroenterology 医学-胃肠肝病学

CiteScore

5.60

自引率

3.40%

发文量

339

审稿时长

3-8 weeks

期刊介绍： Journal of Clinical Gastroenterology gathers the world''s latest, most relevant clinical studies and reviews, case reports, and technical expertise in a single source. Regular features include cutting-edge, peer-reviewed articles and clinical reviews that put the latest research and development into the context of your practice. Also included are biographies, focused organ reviews, practice management, and therapeutic recommendations.